stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Revenue growth
BeOne Medicines Ltd. - Sponsored ADR's revenue growth over the twelve months to 30 September 2026 was 32.9%, down 7.4 percentage points from fiscal 2025 (40.2%). Over the past ten years it has ranged from −87.9% (fiscal 2016) to 22,179.2% (fiscal 2017); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 40.2% | (14.73) |
| FY2024 | 55.0% | (18.69) |
| FY2023 | 73.7% | 53.28 |
| FY2022 | 20.4% | (260.46) |
| FY2021 | 280.8% | 308.70 |
| FY2020 | −27.9% | (143.90) |
| FY2019 | 116.0% | 132.88 |
| FY2018 | −16.9% | (22,196.01) |
| FY2017 | 22,179.2% | 22,267.02 |
| FY2016 | −87.9% | (55.49) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 33.8% | 4.18 |
| Jun 2026 | 29.6% | (5.83) |
| Mar 2026 | 35.5% | 2.62 |
| Dec 2025 | 32.8% | (8.16) |
| 40 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RVMD Revolution Medicines, Inc. compare | 491.1% |
| INSM Insmed, Inc. compare | 240.0% |
| ARGX argenex SE compare | 60.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR | 32.9% |
| INCY Incyte Corporation compare | 24.9% |
| GMAB Genmab A/S Sponsored ADR compare | 22.3% |
| RPRX Royalty Pharma PLC compare | 11.4% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| ROIV Roivant Sciences Ltd. compare | −67.6% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ONC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement